Molecular diagnosis of prostate cancer

被引：3
作者：
Canto E.I. [1 ]
Shariat S.F. [1 ]
Slawin K.M. [1 ]
机构：
[1] Scott Department of Urology, Baylor College of Medicine, The Baylor Prostate Center, 6560 Fannin Street, Suite 2100, Houston, 77030, TX
来源：
Current Urology Reports | 2004年 / 5卷 / 3期
关键词：
Prostate Cancer; Prostate Cancer Detection; Prostate Cancer Screening; Prostate Volume; Seminal Plasma;
D O I：
10.1007/s11934-004-0038-2
中图分类号：
学科分类号：
摘要：
The diagnosis, staging, and management of prostate cancer as we know it today is greatly dependent on our ability to measure serum prostate-specific antigen (PSA) concentration. Nevertheless, because serum PSA concentration, particularly when less than 10 ng/mL, reflects the presence of benign prostatic hyperplasia more often than cancer, there is a clear need for more specific prostate cancer markers. The most promising new markers for prostate cancer are the various molecular forms of free PSA. Mass spectrometry also is emerging as a potential tool in prostate cancer screening. Because it is unlikely that any one marker will have 100% sensitivity and specificity, as new serum markers are tested, nomograms that incorporate multiple independently predictive parameters for the detection of prostate cancer will become indispensable in our efforts to improve prostate cancer screening. © 2004, Current Science Inc.
引用
收藏
页码：203 / 211
页数：8
相关论文
共 59 条
  • [1] Wang M.C., Valenzuela L.A., Murphy G.P., Chu T.M., Purification of a human prostate specific antigen, Invest Urol, 17, pp. 159-163, (1979)
  • [2] Kuriyama M., Wang M.C., Papsidero L.D., Et al., Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay, Cancer Res, 40, pp. 4658-4662, (1980)
  • [3] Stamey T.A., Yang N., Hay A.R., Et al., Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate, N Engl J Med, 317, pp. 909-916, (1987)
  • [4] Roberts R.O., Bergstralh E.J., Katusic S.K., Et al., Decline in prostate cancer mortality from 1980 to 1997 and an update on incidence trends in Olmsted County, Minnesota, J Urol, 161, pp. 529-533, (1999)
  • [5] Ries L.A., Eisner M.P., Kosary C.L., Et al., SEER Cancer Statistics Review, 1973–1998, (2000)
  • [6] Bartsch G., Horninger W., Klocker H., Et al., Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria, Urology, 58, pp. 417-424, (2001)
  • [7] Gore J.L., Shariat S.F., Miles B.J., Et al., Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer, J Urol, 165, pp. 1554-1559, (2001)
  • [8] Kerlikowske K., Grady D., Barclay J., Et al., Positive predictive value of screening mammography by age and family history of breast cancer, JAMA, 270, pp. 2444-2450, (1993)
  • [9] Catalona W.J., Richie J.P., Ahmann F.R., Et al., Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men, J Urol, 151, pp. 1283-1290, (1994)
  • [10] Benson M.C., Whang I.S., Pantuck A., Et al., Prostate-specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer, J Urol, 147, pp. 815-816, (1992)
123456